Exchange: NASDAQ·Updated 03:05 PM EDT
SMMT logo

SMMTSummit Therapeutics Inc

$15.47
$0.165
(1.08%)
Today
EarningsAug 10
Mkt Cap$11.88B
Vol1.81M
News
all
press releases
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on...
Business Wire
News Placeholder
More News
News Placeholder
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsRecursion Pharmaceuticals leverages an artificial intelligence platform to decode biology and automate the drug discovery process...
Nasdaq News: Markets
News Placeholder
The New Cancer Moonshot: Innovative Companies Pursuing Game-Changing Therapies
Cancer treatment is undergoing one of the most significant transformations in modern medical history.
24-7 Market News
News Placeholder
Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
US stock futures lower, Nasdaq down 1%. Super Micro shares down 8.6% after announcing $7B offering to fund AI orders. Other stocks also down in pre-market trading.read more...
Benzinga
News Placeholder
Why Is SMMT Stock Tumbling Today?
Summit announced a common stock offering, with underwriters having a 30-day option to purchase up to an additional $75 million of shares.
Stocktwits
News Placeholder
Summit Therapeutics Announces Proposed Public Offering of Common Stock
Summit Therapeutics Inc. (Nasdaq: SMMT) (Summit, we, or the Company) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant...
Business Wire
News Placeholder
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data...
Yahoo! Finance: News
News Placeholder
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM...
Business Wire
News Placeholder
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
Summit Therapeutics (SMMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
Investors Are Watching This High-Stakes Corner of Biotech
The race to improve therapies is heating up as Wall Street hunts for the next winners. NASDAQ:SPRC, NASDAQ:NTHI, NYSE:JNJ, NASDAQ:SMMT, NASDAQ:BNTX
24-7 Market News
<
1
2
...
>

Advertisement|Remove ads.